ライフサイエンスコーパス: SARS-CoV

1 SARS-CoV-2 has a zoonotic origin and was transmitted to

2 SARS-CoV-2 has been detected in the CSF of some patients

3 SARS-CoV-2 infection is characterized by peak viral load

4 SARS-CoV-2 is a new member of the betacoronavirus genus

5 SARS-CoV-2 is responsible for the development of coronav

6 SARS-CoV-2 MA caused more severe disease in aged mice, a

7 SARS-CoV-2 may modulate macrophage-mediated inflammation

8 SARS-CoV-2 spike glycoprotein (S)-reactive antibodies we

9 SARS-CoV-2 viral loads, especially plasma viremia, are a

10 SARS-CoV-2 was detected by RT-qPCR and viral culture; th

11 SARS-CoV-2-specific memory CD8(+) T cells exhibited func

12 SARS-CoV-2-specific T cell responses were driven by TCR

13 SARS-CoV-2-uninfected donor sera exhibited specific neut

14 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths.

15 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and an existing pandemic of metabolic diseas

16 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remai

17 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and

18 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse transcriptase polymerase ch

19 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China and rapidly spread worldwid

20 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019(1,2) and is respons

21 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has elicited an equally rapid response aimin

22 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in populations, and to verify the developmen

23 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the environment are summarized and discus

24 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into Scotland using a combined phylogenetic

25 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of an ongoing pandemic that has

26 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the currently un

27 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disea

28 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has devastated global public health

29 The SARS coronavirus 2 (SARS-CoV-2) pandemic is a global challenge, which the sc

30 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

31 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients indicate that a cytokine

32 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevalence and the case-fatality rate during

33 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in respiratory samples is the standard m

34 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, used in a combined cocktail (

35 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that results in excessive inflammation and r

36 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission networks became established in

37 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes a pathogenic condition that has been

38 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 and has since become a

39 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a member of the Coronaviridae family of

40 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease

41 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while striving to find a suitable vaccine t

42 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

43 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

44 re acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection increase the risk for acute nonisc

45 to both wild-type (D614) and D614G mutant(2) SARS-CoV-2 as well as CD8(+) T cell responses, and prote

46 human betacoronavirus infection (SARS-CoV-2, SARS-CoV, MERS-CoV, seasonal coronaviruses).

47 m for detection of antibodies to SARS-CoV-2, SARS-CoV-1, MERS, three circulating coronavirus strains

48 spike D614G substitution in the USA-WA1/2020 SARS-CoV-2 strain, and found that it enhances viral repl

49 ere, with a focus on Israel, we sequence 212 SARS-CoV-2 sequences and use them to perform a comprehen

50 two subsequent analyses of 6,228 and 38,248 SARS-CoV-2 genomes which became available later.

51 unctional elements within the massive, ~30kb SARS-CoV-2 RNA genome.

52 Sequencing of 1,314 SARS-CoV-2 viral genomes from available patient samples

53 We analyzed 453 SARS-CoV-2 genomes collected between 20 February and 15

54 Here, we generate 649 SARS-CoV-2 genome sequences from infected patients in Ne

55 globally distributed haplotypes from 15,789 SARS-CoV-2 genomes and model their success based on thei

56 t continued organ transplantation, even in a SARS-CoV-2 hyperendemic area.

57 ut serological assays (HTSAs) and the Abbott SARS-CoV-2 IgG assay quantify levels of antibodies that

58 ify convergence of antibody sequences across SARS-CoV-2-infected patients, highlighting stereotyped n

59 Acute SARS-CoV-2 infection leaves protracted beneficial (ie, a

60 In summary, the mouse-adapted SARS-CoV-2 MA model demonstrates age-related disease pat

61 Additionally, SARS-CoV-2-specific memory lymphocytes exhibited charact

62 ibody responses in children and adults after SARS-CoV-2 infection.

63 ent and to treat the acute lung injury after SARS-CoV-2 infection, especially for those with the ACE

64 not sufficient to prevent transmission after SARS-CoV-2 introduction into this facility.

65 bited specific neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes.

66 erapeutic and/or prophylactic agents against SARS-CoV-2.

67 S adult population formed antibodies against SARS-CoV-2, and fewer than 10% of those with antibodies

68 ifying antiviral compounds effective against SARS-CoV-2.

69 n of commercial antibodies generated against SARS-CoV spike protein and nucleoprotein, double strande

70 e prophylactic effectiveness of IFNs against SARS-CoV-2.

71 or immunoglobulin detection produced against SARS-CoV-2.

72 titres are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune

73 D8(+) T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice with

74 T cell reactivity against SARS-CoV-2 was observed in unexposed people; however, th

75 Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants

76 y-based countermeasures and vaccines against SARS-CoV-2.

77 he origin and emergence of its causal agent, SARS-CoV-2, in the human population remains mysterious,

78 ross 145 HLA-A, -B, and -C genotypes for all SARS-CoV-2 peptides.

79 NAs merit further development as alternative SARS-CoV-2 vaccines.

80 neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes.

81 tion between the detected level of human and SARS-CoV-2 nucleic acids.

82 nowledge regarding genetic polymorphisms and SARS-CoV-2 and COVID-19.

83 ute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating

84 t individuals who were seronegative for anti-SARS-CoV-2 antibodies targeting spike (S) and nucleoprot

85 research needs pertaining to the use of anti-SARS-CoV-2 antibody tests for diagnosis, public health s

86 and subsequently tested with samples of anti-SARS-CoV-2 monoclonal antibody CR3022 (0.1 mug/ml, 1.0 m

87 We then measured the abundance of anti-SARS-CoV-2 S1 IgG in 16 convalescent COVID-19 patients.

88 We found that the Ortho anti-SARS-CoV-2 total Ig and IgG high-throughput serological

89 As SARS-CoV-2 infections and death counts continue to rise,

90 odies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007

91 port the molecular assembly of the authentic SARS-CoV-2 virus using cryoelectron tomography (cryo-ET)

92 ing model to analyze the correlation between SARS-CoV-2 test results and 20 routine laboratory tests

93 ad nanobody candidate, NIH-CoVnb-112, blocks SARS-CoV-2 spike pseudotyped lentivirus infection of HEK

94 ctivator of transcription signaling, boosted SARS-CoV-2 replication in the IFN-competent Calu-3 cells

95 Both SARS-CoV and MERS-CoV have caused serious outbreaks and

96 veillance system for the emergency caused by SARS-CoV-2.

97 macromolecule is involved in ARDS caused by SARS-CoV-2.

98 f neutralizing antibodies (nAbs) elicited by SARS-CoV-2 infection is crucial for understanding immune

99 strains of mice are not readily infected by SARS-CoV-2 because of species-specific differences in th

100 ntify host factors required for infection by SARS-CoV-2 and seasonal coronaviruses, we designed a foc

101 t nucleocapsid antigen specifically captures SARS-CoV-2 antibodies in patient specimens.

102 In Vero E6 and in Calu3 cells, SARS-CoV-2 is substantially attenuated in the context of

103 polymerase (RdRp) are the best characterized SARS-CoV-2 targets and show the highest degree of conser

104 ow present at low frequencies in circulating SARS-CoV-2 populations.

105 onstrate that even under extreme conditions, SARS-CoV-2 virus is unable to replicate in these mosquit

106 Among 51 patients with confirmed SARS-CoV-2 infections, 23 (45.1%), 24 (47.1%), and 22 (4

107 In contrast, SARS-CoV-2 can be detected in the stool of some patients

108 Like other coronaviruses, SARS-CoV-2 is thought to have been transmitted to humans

109 well as severe illness and death (MERS-CoV, SARS-CoV, SARS-CoV-2).

110 dies have shown that, similarly to SARS-CoV, SARS-CoV-2 utilises the Spike glycoprotein on the envelo

111 evere illness and death (MERS-CoV, SARS-CoV, SARS-CoV-2).

112 ulture; the limit of detection for culturing SARS-CoV-2 from surfaces was determined.

113 inical isolate, the infectious-clone-derived SARS-CoV-2 (icSARS-CoV-2) exhibited similar plaque morph

114 portable and real-time POC device to detect SARS-CoV-2 from VTM samples using an additively manufact

115 We were able to detect SARS-CoV-2-specific T cells in 10 of 10 COVID-19 patient

116 c people were less likely to have detectable SARS-CoV-2 in NTS collected at enrollment (8/13 [62%] vs

117 lateral flow immunoassay test that detected SARS-CoV-2 immunoglobulin G (IgG) and immunoglobulin M (

118 rovide a complementary method of determining SARS-CoV-2 infection status, based on a fully independen

119 Recovered individuals developed SARS-CoV-2-specific immunoglobulin (IgG) antibodies, neu

120 tic introduction of at least seven different SARS-CoV-2 lineages into California, including epidemic

121 While essentially all patients displayed SARS-CoV-2-specific antibodies and virus-neutralization

122 sessed risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirm

123 N-gamma protected mice from mortality during SARS-CoV-2 infection, sepsis, hemophagocytic lymphohisti

124 E2 is the receptor for the recently emerging SARS-CoV-2.

125 wed robust induction of chemokines following SARS-CoV-2 infection, similar to what is seen in patient

126 acturers have developed molecular assays for SARS-CoV-2 under the Food and Drug Administration (FDA)

127 rebrospinal fluid analyses were negative for SARS-CoV-2 in all patients tested (n = 39).

128 ic and symptomatic HCWs testing positive for SARS-CoV-2 rapidly declined to near-zero between 25th Ap

129 9 of the 640 throat swabs were positive for SARS-CoV-2 RNA by quantitative PCR, suggesting community

130 lised with pneumonia and tested positive for SARS-CoV-2.

131 ocumented symptoms with testing positive for SARS-CoV-2.

132 necessary for postpandemic preparedness for SARS-CoV-2.

133 Our recommendation for SARS-CoV-2 diagnostic testing is to select an assay with

134 liva offered sensitivity and specificity for SARS-CoV-2 detection comparable to that of the current s

135 We report a reverse genetic system for SARS-CoV-2.

136 Among 3,302 persons tested for SARS-CoV-2 by BinaxNOW TM and RT-PCR in a community sett

137 Study volunteers were tested for SARS-CoV-2 by means of quantitative polymerase-chain-rea

138 , 433 (64.8%) had previously been tested for SARS-CoV-2 RNA, and 50.0% had a positive RT-PCR result.

139 protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to t

140 uld potentially be developed to protect from SARS-CoV-2 and some other SARS-like viruses that might s

141 non-structural and accessory) proteins from SARS-CoV-2 using predictive algorithms to identify poten

142 emergence, plus 64 pandemic-era samples from SARS-CoV-2 PCR-negative patients with respiratory sympto

143 RS-CoV-2 Spike-pseudotyped virus and genuine SARS-CoV-2 infections are generally restricted by human

144 pants with acute smell and/or taste loss had SARS-CoV-2 antibodies; of these, 39.8% (n = 175) had nei

145 Understanding how SARS-CoV-2 enters human cells is a high priority for dec

146 However, SARS-CoV-2 sera generally lacked cross-neutralization to

147 sons learned from cancer research may impact SARS-CoV-2 research and vice versa.

148 Importantly, SARS-CoV-2-specific T cells were detectable in antibody-

149 tive PUIs (n = 30) and viral coinfections in SARS-CoV-2 RT-PCR-positive PUIs (n = 45).

150 NVs may become an important consideration in SARS-CoV-2 classification and surveillance.

151 ecific CD8(+) T cells and were detectable in SARS-CoV-2 convalescent individuals who were seronegativ

152 ted benefits of lung function improvement in SARS-CoV infections, it has been hypothesized that the b

153 equencies of alternative viral infections in SARS-CoV-2 RT-PCR-negative PUIs (n = 30) and viral coinf

154 with renin-angiotensin system inhibitors in SARS-CoV-2 may outweigh the risks and at the very least

155 table using a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly

156 90% of the neutralizing activity present in SARS-CoV-2 immune sera.

157 he absence of the polybasic cleavage site in SARS-CoV-2 did not affect virus replication in Vero or V

158 centers in March through May 2020, including SARS-CoV-2 testing, well-child visits, HbA(1c) testing,

159 and fecal spread of enteric CoVs, including SARS-CoV-2.

160 like other closely related viruses including SARS-CoV and Middle East respiratory syndrome coronaviru

161 apacity and fate of pre-existing and induced SARS-CoV-2-specific CD8(+) T cell responses during the n

162 ex vivo analysis of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells, applying peptide-loa

163 plicated in human betacoronavirus infection (SARS-CoV-2, SARS-CoV, MERS-CoV, seasonal coronaviruses).

164 ce stability was assessed using infectivity, SARS-CoV-2 survived on stainless steel, plastic, and nit

165 sults reveal possible mechanisms influencing SARS-CoV-2 infectivity and COVID-19 clinical outcomes.

166 omycin were confirmed to effectively inhibit SARS-CoV-2 replication in vitro with EC50 values of 0.00

167 potential therapies and vaccines to inhibit SARS-CoV-2 infection and ameliorate disease is the lack

168 brain organoids as a platform to investigate SARS-CoV-2 infection susceptibility of brain cells, mech

169 We investigated SARS-CoV-2 potential tropism by surveying expression of

170 vivo RNA-RNA interactome of the full-length SARS-CoV-2 genome and subgenomic mRNAs.

171 re utilized to compare Veritor with the Lyra SARS-CoV-2 PCR assay (Lyra).

172 The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for t

173 evidence that complement function modulates SARS-CoV-2 infection outcome, the data point to putative

174 We find that most SARS-CoV-2 infections sampled during this time derive fr

175 hether they develop and sustain multifaceted SARS-CoV-2-specific immunological memory.

176 The COVID-19 pandemic caused by the new SARS-CoV-2 coronavirus has imposed severe challenges on

177 Notably, SARS-CoV-2 S variants that resist commonly elicited neut

178 019 (COVID-19), which is caused by the novel SARS-CoV-2, continues to spread rapidly around the world

179 It should increase the availability of SARS-CoV-2 testing as well as expand the settings in whi

180 atic function was mediated by the binding of SARS-CoV-2 spike RBD domain.

181 Knowing the concentration of SARS-CoV-2 S1-specific IgG is crucial in selecting appro

182 All patients had laboratory confirmation of SARS-CoV-2 infection.

183 susceptibility to and the natural course of SARS-CoV-2 infection.

184 cell responses during the natural course of SARS-CoV-2 infection.

185 cm(-2), respectively, toward detection of SARS-CoV-2 in biological media, while blind clinical eva

186 COVID-19 that may facilitate development of SARS-CoV-2 therapeutics and vaccines.

187 The emergence of SARS-CoV-2 has driven a global research effort to identi

188 The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000

189 , and be a key component in the evolution of SARS-CoV-2 with this structural loop affecting virus sta

190 ntial to chart the architectural features of SARS-CoV-2 and pinpoint regions that merit focused study

191 nt positions throughout the entire genome of SARS-CoV-2.

192 ospitals from becoming independent 'hubs' of SARS-CoV-2 transmission, and illustrate how, with approp

193 y and on projections of the global impact of SARS-CoV-2 on the human population, and assess its plaus

194 We investigated the incidence of SARS-CoV-2 infection confirmed by polymerase chain react

195 of age and females had a lower incidence of SARS-CoV-2 infection than adolescents or adults and male

196 D-19 showed a highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers after sympt

197 o show that template-dependent inhibition of SARS-CoV-2 RdRp by RDV is biologically relevant.

198 We also describe potent inhibition of SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020 by Apilimod.

199 Thus, the K18-hACE2 model of SARS-CoV-2 infection shares many features of severe COVI

200 y of remdesivir in a rhesus macaque model of SARS-CoV-2 infection(9).

201 from the United States to inform a model of SARS-CoV-2 transmission.

202 ), S1+S2, nucleocapsid, and ORF6 to ORF10 of SARS-CoV-2, to the HCoV-OC43 and HCoV-HKU1 betacoronavir

203 ilding on knowledge of previous outbreaks of SARS-CoV-1 and Middle East respiratory syndrome (MERS),

204 %, 99%] specificity in predicting outcome of SARS-CoV-2 pneumonia.

205 ortant for understanding the pathogenesis of SARS-CoV-2, vaccine development, and therapeutic testing

206 The excretion pathomechanisms of SARS-CoV-2 are actually unknown.

207 n strategies must target both the potency of SARS-CoV-2 and its evasiveness.

208 We document the presence of SARS-CoV-2 RNA associated with platelets of COVID-19 pat

209 Antibody to the nucleocapsid protein of SARS-CoV-2 is more sensitive than spike protein antibody

210 s study characterizes the trends in rates of SARS-CoV-2 positive test results among individuals in th

211 The estimated odds ratio of SARS-CoV-2 prevalence between the cancer cohort and cont

212 coated with receptor binding domain (RBD) of SARS-CoV-2 spike protein, and subsequently tested with s

213 Low copy numbers (>=500 copies/reaction) of SARS-CoV-2 RNA were consistently detected by the multipl

214 p of ISMs to phylogenetic reconstructions of SARS-CoV-2 evolution, and therefore, ISMs can play an im

215 The relationship of SARS-CoV-2 pulmonary infection and severity of disease i

216 As a result of SARS-CoV-2 binding, ACE2 downregulation enhances the ang

217 lity score that predicts an elevated risk of SARS-CoV-2 infection for multiple species including hors

218 possible postpandemic circulating season of SARS-CoV-2 and add to the knowledge pool necessary for p

219 udy aimed to determine the seroprevalence of SARS-CoV-2 antibodies in a community-based population wi

220 The international spread of SARS-CoV-2 is associated with the ease of global travel,

221 rings) that could help control the spread of SARS-CoV-2, particularly in hard-hit regions.

222 Despite the ability to dampen the spread of SARS-CoV-2, the causative agent of the diseases, through

223 tation (D839Y/N/E) from a European strain of SARS-CoV-2.

224 The spike protein on the surface of SARS-CoV-2 is a major antigen and its engagement with hu

225 onaviruses 229E and OC43, as well as that of SARS-CoV-2.

226 Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were

227 vailable data on the risk of transmission of SARS-CoV-2 through organ transplantation.

228 ole in the pathogenicity and transmission of SARS-CoV-2.

229 Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testi

230 Research on SARS-CoV-2, as well as the closely related SARS-CoV-1 an

231 ses (CoVs) identified in bats and pangolins, SARS-CoV-2 harbors a polybasic furin cleavage site in it

232 e obtained at least 14 days after a positive SARS-CoV-2 PCR.

233 VID-19 were defined as those with a positive SARS-CoV-2 test.

234 .9% NaCl prevents cellular infection with pp-SARS-CoV-2 spike.

235 ective antiviral that can be used to prevent SARS-CoV-2 infection.

236 ing and contact tracing could have prevented SARS-CoV-2 outbreaks from becoming established in these

237 All MIS-C patients had evidence of prior SARS-CoV-2 exposure, mounting an antibody response with

238 noids from hiPSCs and showed that productive SARS-CoV-2 infection of these organoids is associated wi

239 argeting 332 members of a recently published SARS-CoV-2 protein interactome.

240 Rapid SARS-CoV-2 countermeasure development is contingent on t

241 n SARS-CoV-2, as well as the closely related SARS-CoV-1 and MERS coronaviruses, is restricted to BSL-

242 tourists and a family of 5 French residents; SARS-CoV-2 was detected in 5 individuals in France, 6 in

243 hage libraries that specifically bind the S1 SARS-CoV-2 spike protein, and block the interaction with

244 our findings provide evidence for selective SARS-CoV-2 neurotropism and support the use of hiPSC-der

245 The haplotypes of the sequenced SARS-CoV-2 viruses were diverse and changed over time.

246 on-gamma-based assays with peptides spanning SARS-CoV-2 except ORF1.

247 ant to mutation compared to species-specific SARS-CoV-2 RT-PCR assays.

248 patient samples enabled us to estimate that SARS-CoV-2 was introduced to Scotland on at least 283 oc

249 Modeling indicates that SARS-CoV-2 control requires the synergistic efforts of c

250 Extensive studies have revealed that SARS-CoV-2 shares many biological features with SARS-CoV

251 Here we show that SARS-CoV-2 causes a respiratory disease in rhesus macaqu

252 We show that SARS-CoV-2 Spike-pseudotyped virus and genuine SARS-CoV-

253 s collected within a 2-day period around the SARS-CoV-2 test date.

254 The COVID-19 pandemic caused by the SARS-CoV-2 has recently emerged as a serious jolt to hum

255 e 2019 (COVID-19), the illness caused by the SARS-CoV-2 virus, is rapidly spreading throughout the wo

256 e present a self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated within a lipid nan

257 CoV (MERS-CoV), bat CoV HKU5 expressing the SARS-CoV-1 spike, and vesicular stomatitis virus (VSV) e

258 icular stomatitis virus (VSV) expressing the SARS-CoV-2 spike.

259 dentify patients more likely to die from the SARS-CoV-2 infection, regardless of age.

260 lights proteolytic degeneracy wired into the SARS-CoV-2 lifecycle.

261 le organ failure, suggesting a spread of the SARS-CoV-2 in blood.

262 iliated cells as potential reservoirs of the SARS-CoV-2 receptor.

263 leavage contributes to the activation of the SARS-CoV-2 S glycoprotein, we evaluated the ability of p

264 al dispersal and increasing frequency of the SARS-CoV-2 spike protein variant D614G are suggestive of

265 nt of guidance to reduce transmission of the SARS-CoV-2 virus, responsible for the COVID-19 pandemic.

266 An essential protein of the SARS-CoV-2 virus, the envelope protein E, forms a homope

267 ate-dependent epidemic model to simulate the SARS-CoV-2 pandemic by probing different scenarios based

268 We reveal that the SARS-CoV-2 virus becomes more infectious.

269 Strikingly, unlike the SARS-CoV-2-like coronaviruses (CoVs) identified in bats

270 Antibodies to SARS-CoV-2 predicted the odds of developing acute respir

271 AIR) platform for detection of antibodies to SARS-CoV-2, SARS-CoV-1, MERS, three circulating coronavi

272 n contrast to mice, are highly permissive to SARS-CoV-2 and develop bronchopneumonia and strong infla

273 veolar type-II-like cells) are permissive to SARS-CoV-2 infection, and showed robust induction of che

274 do not know regarding our immune response to SARS-CoV-2, and provide a number of scenarios for which

275 found sex differences in immune responses to SARS-CoV-2 and the predictors of disease progression.

276 Antibody responses to SARS-CoV-2 are unimodally distributed over a broad range

277 protective or pathogenic immune responses to SARS-CoV-2 infection remains unknown.

278 of the Spanish population is seronegative to SARS-CoV-2 infection, even in hotspot areas.

279 Recent studies have shown that, similarly to SARS-CoV, SARS-CoV-2 utilises the Spike glycoprotein on

280 y to the S protein and neutralized wild-type SARS-CoV-2 virus in a synergistic manner.

281 e of the entry receptor is key to understand SARS-CoV-2 tropism, transmission and pathogenesis.

282 cluding in infections with the related virus SARS-CoV.

283 n the context of IFN-I pretreatment, whereas SARS-CoV is not.

284 goal of this study was to determine whether SARS-CoV-2 RNA could be detected from NP samples via a d

285 However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies i

286 -driven BCR clusters closely associated with SARS-CoV-2 antibodies.

287 me-wide CRISPR screens in Vero-E6 cells with SARS-CoV-2, Middle East respiratory syndrome CoV (MERS-C

288 ing infection of AT2 and basal cultures with SARS-CoV-2 and identifying club cells as a target popula

289 S-CoV-2 shares many biological features with SARS-CoV, the zoonotic virus that caused the 2002 outbre

290 red information on 94 patients with IEI with SARS-CoV-2 infection.

291 of individuals that have been infected with SARS-CoV-2 even if the infection was asymptomatic.

292 y and high-risk APOL1 genotype infected with SARS-CoV-2 have emerged during the COVID-19 pandemic.

293 Although the diagnosis of infection with SARS-CoV-2 is microbiological, imaging techniques play a

294 Infection with SARS-CoV-2 occurred in 42 participants recommended masks

295 nanswered question is whether infection with SARS-CoV-2 results in protective immunity against reexpo

296 VID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic i

297 We challenge organoids with SARS-CoV-2 spike pseudovirus and live virus to demonstra

298 mell was more prevalent in participants with SARS-CoV-2 antibodies, compared with those without antib

299 nt it is unclear how common reinfection with SARS-CoV-2 is and how long serum antibodies and virus-sp

300 ed symptoms in participants with and without SARS-CoV-2 antibodies.